scholarly journals Randomized trials with missing outcome data: how to analyze and what to report

2014 ◽  
Vol 186 (15) ◽  
pp. 1153-1157 ◽  
Author(s):  
Rolf H.H. Groenwold ◽  
Karel G.M. Moons ◽  
Jan P. Vandenbroucke
Keyword(s):  
Randomized Trials ◽  
Outcome Data

Using generalized estimating equations and extensions in randomized trials with missing longitudinal patient reported outcome data

2018 ◽  
Vol 27 (9) ◽  
pp. 2125-2131 ◽  
Author(s):  
Melanie L. Bell ◽  
Nicholas J. Horton ◽  
Haryana M. Dhillon ◽  
Victoria J. Bray ◽  
Janette Vardy
Keyword(s):  
Generalized Estimating Equations ◽  
Randomized Trials ◽  
Estimating Equations ◽  
Patient Reported Outcome ◽  
Outcome Data ◽  
Patient Reported ◽  
Generalized Estimating

Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next

2019 ◽  
Vol 53 (4) ◽  
pp. 325-336 ◽  
Author(s):  
Mostafa R. Amer ◽  
Surya Teja Chaturvedula ◽  
Saurabh Joshi ◽  
Joseph Ingrassia
Keyword(s):  
Clinical Practice ◽  
Peripheral Arterial Disease ◽  
Antithrombotic Therapy ◽  
Randomized Trials ◽  
Arterial Disease ◽  
Outcome Data ◽  
Significant Heterogeneity ◽  
Treatment Protocols ◽  
Peripheral Arterial

Objective: The optimal antithrombotic regimen in peripheral arterial disease (PAD) is not known, leading to significant variations in antithrombotic treatment protocols in randomized trials and clinical practice. In device trials, antithrombotic regimens in patients receiving peripheral vascular interventions have not been clearly reported on. This review summarizes and discusses the most recent evidence on this topic to provide a potential guide to clinical practice. Methods: A search of the literature was done for publications that reported outcomes of major PAD device trials. Reported outcomes and various antithrombotic regimens were studied. Results: Use of antithrombotic therapy varied significantly between various device trials. Reporting of antithrombotic regimens at the time of follow-up is lacking. Conclusion: Outcome data on optimal antithrombotic regimens are presently lacking largely due to the significant heterogeneity and underreporting of antithrombotic regimens at follow-up among prior clinical trials. Standardization and reporting of precise antithrombotic regimens at various points of follow-up in device trials of patients with PAD should be attempted so as to minimize differences in treatment patterns when evaluating new devices.

Multiple imputation for handling missing outcome data in randomized trials involving a mixture of independent and paired data

2021 ◽  
Author(s):  
Thomas R. Sullivan ◽  
Lisa N. Yelland ◽  
Margarita Moreno‐Betancur ◽  
Katherine J. Lee
Keyword(s):  
Multiple Imputation ◽  
Randomized Trials ◽  
Outcome Data ◽  
Paired Data

scholarly journals Dealing With Missing Outcome Data in Randomized Trials and Observational Studies

2011 ◽  
Vol 175 (3) ◽  
pp. 210-217 ◽  
Author(s):  
Rolf H. H. Groenwold ◽  
A. Rogier T. Donders ◽  
Kit C. B. Roes ◽  
Frank E. Harrell ◽  
Karel G. M. Moons
Keyword(s):  
Observational Studies ◽  
Randomized Trials ◽  
Outcome Data

scholarly journals Neoadjuvant therapy of locally/regionally advanced melanoma

2019 ◽  
Vol 11 ◽  
pp. 175883591986695 ◽  
Author(s):  
Arjun Khunger ◽  
Zachary S. Buchwald ◽  
Michael Lowe ◽  
Mohammad K. Khan ◽  
Keith A. Delman ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Neoadjuvant Therapy ◽  
Randomized Trials ◽  
Tumor Response ◽  
Outcome Data ◽  
Advanced Melanoma ◽  
Clinical Activity ◽  
Term Outcome ◽  
Long Term Outcome

Locally/regionally advanced melanoma confers a major challenge in terms of surgical and medical management. Surgical treatment carries the risks of surgical morbidities and potential complications that could be lasting. In addition, these patients continue to have a high risk of relapse and death despite the use of standard adjuvant therapy. Neoadjuvant therapy has the potential to significantly improve the clinical outcome of these patients, particularly in this era of newer and effective targeted and immunotherapeutic agents. Previous neoadjuvant studies tested chemotherapy with temozolomide where the clinical activity was limited. Biochemotherapy (BCT) was tested in two studies in the neoadjuvant setting and showed high tumor response rates; however, BCT was ultimately abandoned following its failure to demonstrate survival benefits in randomized trials of metastatic disease. Success of immunotherapy and targeted therapy in prolonging the lives of patients with metastatic melanoma generated considerable interest to investigate these novel strategies in the adjuvant and neoadjuvant settings. A number of neoadjuvant targeted and immunotherapy studies have been completed in melanoma to date and have yielded promising clinical activity. Given these encouraging results, a number of studies with other molecularly targeted and immunotherapeutic agents and their combinations are ongoing in the neoadjuvant setting; long-term outcome data are eagerly awaited. Such studies also provide access to biospecimens before and during therapy, allowing for the conduct of biomarker and mechanistic studies that may have a significant impact in guiding adjuvant therapy choices and drug development.

Sign in / Sign up

Export Citation Format

Share Document